IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v124y2020i4p397-403.html
   My bibliography  Save this article

The Portuguese generic medicines market: What’s next?

Author

Listed:
  • Nunes, Alexandre Morais
  • Ferreira, Diogo Cunha
  • de Matos, Andreia
  • Julião, Rui Miranda

Abstract

Brand-name medicines have dominated the Portuguese market for several decades with unquestionable exclusivity. This resulted particularly from the absence of a requirement of prescriptions by international non-proprietary name. To promote the enhancement of both efficiency and sustainability in the health system, the Portuguese government introduced the generics in Portugal by the 90 s. However, only in the first decade of the 21st century were some policies implemented to increase their market share. Although some expectations were created, the use of generics has increased moderately during that period, in which policies to promote them were consolidated by imposing the austerity principles in the midst of the economic and social crisis. This study analyses the main policy measures already implemented as well as the incentives created for the replacement of brand-name medicines with generics. In addition, the present study also makes some recommendations to promote a broader and better use of generics in Portugal.

Suggested Citation

  • Nunes, Alexandre Morais & Ferreira, Diogo Cunha & de Matos, Andreia & Julião, Rui Miranda, 2020. "The Portuguese generic medicines market: What’s next?," Health Policy, Elsevier, vol. 124(4), pages 397-403.
    • Handle: RePEc:eee:hepoli:v:124:y:2020:i:4:p:397-403
    DOI: 10.1016/j.healthpol.2020.02.014
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S016885102030049X
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2020.02.014?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Balasopoulos, T. & Charonis, A. & Athanasakis, K. & Kyriopoulos, J. & Pavi, E., 2017. "Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions," Health Policy, Elsevier, vol. 121(3), pages 265-272.
    2. Skipper, Niels & Vejlin, Rune, 2015. "Determinants of generic vs. brand drug choice: Evidence from population-wide Danish data," Social Science & Medicine, Elsevier, vol. 130(C), pages 204-215.
    3. Skaltsas, Leonora N. & Vasileiou, Konstantinos Z., 2015. "Patients’ perceptions of generic drugs in Greece," Health Policy, Elsevier, vol. 119(11), pages 1406-1414.
    4. Sonal Singh, 2018. "The Safety of Generic Prescription Drugs in the United States," Drug Safety, Springer, vol. 41(4), pages 325-328, April.
    5. Barros, Pedro Pita, 2012. "Health policy reform in tough times: The case of Portugal," Health Policy, Elsevier, vol. 106(1), pages 17-22.
    6. Wagner, Todd H. & Heisler, Michele & Piette, John D., 2008. "Prescription drug co-payments and cost-related medication underuse," Health Economics, Policy and Law, Cambridge University Press, vol. 3(1), pages 51-67, January.
    7. Zerbini, Cristina & Luceri, Beatrice & Vergura, Donata Tania, 2017. "Leveraging consumer’s behaviour to promote generic drugs in Italy," Health Policy, Elsevier, vol. 121(4), pages 397-406.
    8. Bate, Roger & Jin, Ginger Zhe & Mathur, Aparna, 2011. "Does price reveal poor-quality drugs? Evidence from 17 countries," Journal of Health Economics, Elsevier, vol. 30(6), pages 1150-1163.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Arantes, Amílcar & Alhais, Andreia Frias & Ferreira, Luis Miguel D.F., 2022. "Application of a purchasing portfolio model to define medicine purchasing strategies: An empirical study," Socio-Economic Planning Sciences, Elsevier, vol. 84(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lins Ferreira, Vinicius & Pereira da Veiga, Cássia Rita & Kudlawicz-Franco, Claudineia & Scalercio, Priscila & Ramires, Yohanna & Pontarolo, Roberto & Carvalho, Denise Maria W. & da Veiga, Claudimar , 2017. "Generic drugs in times of economic crisis: Are there changes in consumer purchase intention?," Journal of Retailing and Consumer Services, Elsevier, vol. 37(C), pages 1-7.
    2. Roger Bate & Ginger Zhe Jin & Aparna Mathur, 2012. "In Whom We Trust: The Role of Certification Agencies in Online Drug Markets," NBER Working Papers 17955, National Bureau of Economic Research, Inc.
    3. Aida Isabel Tavares & Inês Marques, 2021. "Multi-layer health insurance coverage, medical services use and health in a Universal National Health System, the case of Portugal," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 141-153, February.
    4. Nicholas Wilson, 2015. "Can Disease-Specific Funding Harm Health? in the Shadow of HIV/AIDS Service Expansion," Demography, Springer;Population Association of America (PAA), vol. 52(5), pages 1671-1700, October.
    5. Granlund, David & Sundström, David, 2018. "Physicians prescribing originals causes welfare losses," Economics Letters, Elsevier, vol. 170(C), pages 143-146.
    6. Mondelo-García, Cristina & Mendoza, Elvia & Movilla-Fernández, María-Jesús & Coronado, Carmen, 2018. "Perceptions of pharmacists and physicians on generic substitution in a financial crisis context in Northwestern Spain: A qualitative study," Health Policy, Elsevier, vol. 122(12), pages 1316-1325.
    7. Clemens, Timo & Michelsen, Kai & Commers, Matt & Garel, Pascal & Dowdeswell, Barrie & Brand, Helmut, 2014. "European hospital reforms in times of crisis: Aligning cost containment needs with plans for structural redesign?," Health Policy, Elsevier, vol. 117(1), pages 6-14.
    8. Daniel Bennett & Wesley Yin, 2014. "The Market for High-Quality Medicine," NBER Working Papers 20091, National Bureau of Economic Research, Inc.
    9. Magda Wladysiuk & Aleksander Araszkiewicz & Brian Godman & Katarzyna Szabert & Corrado Barbui & Alan Haycox, 2011. "Influence of patient co-payments on atypical antipsychotic choice in Poland," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 101-110, March.
    10. Roger Bate & Ginger Zhe Jin & Aparna Mathur, 2012. "Counterfeit or Substandard? Assessing Price and Non-Price Signals of Drug Quality," NBER Working Papers 18073, National Bureau of Economic Research, Inc.
    11. Fiorentini, Gianluca & Bruni, Matteo Lippi & Mammi, Irene, 2022. "The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 37-68.
    12. Lin, Yu-Shiuan & Lin, Min-Ting & Cheng, Shou-Hsia, 2019. "Drug price, dosage and safety: Real-world evidence of oral hypoglycemic agents," Health Policy, Elsevier, vol. 123(12), pages 1221-1229.
    13. Marina Economou & Lily Evangelia Peppou & Kyriakos Souliotis & Helen Lazaratou & Konstantinos Kontoangelos & Sofia Nikolaidi & Alexandra Palli & Costas N Stefanis, 2019. "Attitudes to depression and psychiatric medication amid the enduring financial crisis in Attica: Comparison between 2009 and 2014," International Journal of Social Psychiatry, , vol. 65(6), pages 479-487, September.
    14. Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
    15. Yasar A. Ozcan & Jaya Khushalani, 2017. "Assessing efficiency of public health and medical care provision in OECD countries after a decade of reform," Central European Journal of Operations Research, Springer;Slovak Society for Operations Research;Hungarian Operational Research Society;Czech Society for Operations Research;Österr. Gesellschaft für Operations Research (ÖGOR);Slovenian Society Informatika - Section for Operational Research;Croatian Operational Research Society, vol. 25(2), pages 325-343, June.
    16. Tavares, Lara Patrício & Zantomio, Francesca, 2017. "Inequity in healthcare use among older people after 2008: The case of southern European countries," Health Policy, Elsevier, vol. 121(10), pages 1063-1071.
    17. Levaggi, Rosella & Marcantoni, Claudio & Filippucci, Laura & Gelatti, Umberto, 2012. "Not a good buy: Value for money of prescription drugs sold on the Internet," Health Policy, Elsevier, vol. 106(3), pages 241-245.
    18. Goldsmith, Laurie J. & Kolhatkar, Ashra & Popowich, Dominic & Holbrook, Anne M. & Morgan, Steven G. & Law, Michael R., 2017. "Understanding the patient experience of cost-related non-adherence to prescription medications through typology development and application," Social Science & Medicine, Elsevier, vol. 194(C), pages 51-59.
    19. Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2014. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," Journal of Health Economics, Elsevier, vol. 36(C), pages 174-187.
    20. Adrienne M. Lucas & Nicholas L. Wilson, 2018. "Can At-Scale Drug Provision Improve the Health of the Targeted in Sub-Saharan Africa?," American Journal of Health Economics, University of Chicago Press, vol. 4(3), pages 358-382, Summer.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:124:y:2020:i:4:p:397-403. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.